Immupharma Share Discussion Threads

[ny boy] 08/12/2017 09:36

It’s clear from the price action each week, every so often they drop the bid, widen the spread and try and weed up (mugging) weak holders, doubters, basically the ones that don’t get it, then the share price moves higher. Most are just buying and holding for the “main events” that will kick off end of January onwards, which is now only 34 trading days away.

Less big sellers lining up on Level 2 than a few days ago, more buyers, more holding, sooner or later we will get another 10-20p rise, due to shortage of stock.

Level 3 v 1 strong buying interest building

[hamhamham1] 08/12/2017 09:31

Its probably my broker again, but can anyone buy any IMM shares currently - last 10 mins seem to be none up for grabs? Not trying to ramp, just a question.

[qs99] 08/12/2017 09:30

definitely looks like it is trying hard to break out IMO!

[ny boy] 08/12/2017 09:07

Well done Divmad & GL to everyone whatever their strategy is.

[divmad] 08/12/2017 07:52

Been here since 2013. Lowest buy at 25p. Sold down to free ride level now. Hoping to make a million at £16.

[ny boy] 08/12/2017 07:39

Ignore the noise, I have been since early 50p’s

[kensingtoncourt] 08/12/2017 07:24

Yes it's all looking very good.

[ewads] 08/12/2017 07:19

If something looks too good.......

[l0ngterm] 08/12/2017 00:03

Butler: so you got in early or late.To put that in context 130 4+ years ago or 25p a year or so ago, minutes, please quantify?You say 100% profit is bad.. hmm show me something better...Shall I carry on?

[butler4] 07/12/2017 23:31

Absolutely not

[ny boy] 07/12/2017 23:28

Sounds like you weren’t an early investor in bitcoin then 🙄

[butler4] 07/12/2017 23:07

We’re all in make believe land - we will only make money if the results are positive and that is a guessing game - but let’s assume it’s all good - then Imm makes a deal with a major pharmaceutical company and that company will be looking to make a significant profit - I would suggest that the best that we (us small shareholders) can look to gain is a relatively small - say 100-150 per cent - and that’s if we’re smart and sell at the right time. The market will work against us so we have to be smart with our timing.
Its a tricky business - the major players in this stock are not on our Side!

[ny boy] 07/12/2017 21:47

Time is closing in fast, only 10 1/2 trading days to Xmas

34 trading days, give or take the odd half to end of January, the share price should nudge higher 1-2p a day, until the first significant news.

[l0ngterm] 07/12/2017 21:40

Greedfear; not reallyCan you expand on why these companies had a such a rise?Their history?How this transfers over to IMM?Or were you making another point?

[greedfear] 07/12/2017 21:34

.


Interesting facts:

"By Jason Stutman | Dec. 07 2017 - Baltimore, MD

From $0.10 to $170.04?

That’s exactly what Amgen did
And it's far from the only biotech to have made ridiculous gains like this over the years.

Gilead Sciences went from $0.65 to $117.86... Celgene from $0.29 to $131.25...

And Biogen from $0.41 to $422.24...

I could go on all day, but you get the picture."



.

[l0ngterm] 07/12/2017 20:46

While we wait folks, the below link is to a paper on autophagy written in 2014. For those that are interested in why the mechanism of action could be adaptable to other diseases etc.http://onlinelibrary.wiley.com/store/10.1111/bph.12792/asset/bph12792.pdf?v=1&t=jawy9jxs&s=9899b997b47ef139cc163dc69fa2c7ba068a54f0

[blackbear] 07/12/2017 19:47

Could get an update any day now, should push up to 150.

[ny boy] 07/12/2017 18:28

Another solid buying day, another day closer

[sicilian_kan] 07/12/2017 16:12

hottingup, they are on the patent, link below:

[kensingtoncourt] 07/12/2017 15:56

keep it coming money maker. There's nothing wrong with a few reminders how good this is.

[hottingup] 07/12/2017 15:45

s-k in your heading where did you get Bullouis Diseases and Mixed Connective Tissue diseases from, for possible additional indications for Lupuzor?

Also some of your revenue figures are out of date.


This is what I have sourced from IMM's website, the Lupus symposium and recent patent announcement:


From IMM's updated website:



A shift in treating auto-immune disease

"This targeted approach marks a paradigm shift in treating autoimmune disease. Instead of shutting down otherwise healthy immune responses the T-cells are suppressed leaving the immune system modified but intact."

Autophagy represents a key pathway

"Autophagy represents a key pathway that is targeted by the P140/Lupuzor™ peptide. Defects in this complex process underlie many types of diseases, including autoimmune, many inflammatory diseases, and degenerative neurological illnesses (e.g. Parkinson’s and Alzheimer’s diseases), and aging. Thus, therapeutic agents such as P140/Lupuzor™, are unique molecules that may significantly slow down or correct the course of such diseases and considerably improve the quality of the life of patients."



Forigerimod/PI40 targeting major auto-immune disease indications

"ImmuPharma together with Professor Sylviane Muller, Lupuzor’s inventor, have presented new evidence supporting Lupuzor’s™ Forigerimod / P140 peptide activity in several other major auto-immune disease indications outside of Lupus including Rheumatoid Arthritis, Crohn’s Disease, and Asthma. In particular, the peptide appears to have general effects against chronic inflammatory indications. Other pre-clinical evidence supports the molecule’s use in: Neuropsychiatric lupus (NPSLE); Gougerot-Sjögren syndrome (GSS); and Guillain-Barre disease (chronic/CIDP)."

Lupuzor™ Symposium
8th June 2016 - 3:35 pm

41 min 40 sec onwards:


Indications with promising data:
- Systemic Lupus Erythematosus (SLE) (Market size $4 bn) (SLE ends Phase 3, Q1 2018)
- Neuropsychiatric lupus (NPSLE)
- Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024)
- Rheumatoid Arthritis (Market size $28.5 bn by 2025)
- Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024)
- Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022)
- Guillan-Barre disease ($520m)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Asthma (Market size $20.7 bn in 2015)

Other potential evaluations:
- Scleroderma (Systemic Sclerosis, Raynaud)
- Psoriasis
- Multiple Sclerosis (MS) (Market size $20 bn by 2024)
- (Others to follow)

Negative preclinical results for potential re-evaluation:
- Type I Diabetes (Market size $43 bn by 2021)
- Amytrophic Lateral Sclerosis (ALS)

IMM have a new Lupuzor patent (granted 2017) covering key markets (USA, EU, China, India & Japan) to 2032 & use in the majority of autoimmune indications. A new patent has also been filed to cover non-autoimmune indications. (IMM, Sep 2017)

[greedfear] 07/12/2017 15:45

ewads- that's sound advice. Alas that won't do for all the people that get annoyed. They want others with different opinions to shut up. Why? Because they think they know better. Do they now? Numerous times I've seen shares reach share price levels that nobody would have predicted. I'm sure a lot of others have too.
I don't see any impossible numbers here. High? Sure. Impossible? No.